Culley Brian M 4
4 · Lineage Cell Therapeutics, Inc. · Filed Feb 14, 2023
Insider Transaction Report
Form 4
Culley Brian M
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Shares, no par value
2023-02-11+31,249→ 139,143 total - Tax Payment
Common Shares, no par value
2023-02-11$1.35/sh−12,744$17,204→ 126,399 total - Exercise/Conversion
Restricted Stock Units
2023-02-11−31,249→ 93,748 totalExercise: $0.00→ Common Shares (31,249 underlying)
Footnotes (4)
- [F1]Shares earned by the Reporting Person as a result of the vesting of a portion of Restricted Stock Units ("RSUs") granted to the Reporting Person on February 11, 2022. RSUs convert into common shares on a one-for-one basis.
- [F2]Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this Report or shares that may be acquired upon the exercise of certain stock options.
- [F3]Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 31,249 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction.
- [F4]The Reporting Person was granted RSUs on February 11, 2022 that vested with respect to 25% of the shares subject to the award on February 11, 2023, and the balance will vest in 3 equal annual installments on each anniversary date thereafter.